Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
OTCMKTS:MRMD

MariMed Q3 2026 Earnings Date & Estimates

MariMed logo
$0.05 0.00 (-5.71%)
As of 10/23/2026 03:58 PM Eastern

MariMed is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for November 12, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MariMed in Q3 2026

MariMed is expected to post earnings of -$0.01 per share on revenue of $41.20 million. In the same quarter a year earlier MariMed reported -$0.01 per share on revenue of $40.76 million. MariMed last reported on August 12, 2026, posting -$0.01 per share and matching the -$0.01 consensus estimate. MariMed has beaten the consensus EPS estimate in 0 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.01
Expected Revenue
$41.20 million
Prior-Year EPS
-$0.01
Prior-Year Revenue
$40.76 million
Expected Revenue Growth
+1.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Met Expectations)
Last Quarter Revenue
$41.93 million
EPS Beat Rate
0 of last 8 quarters

Prepare for the Q3 2026 Call

MariMed Q3 2026 Earnings FAQ

MariMed (OTCMKTS:MRMD) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

MariMed's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MariMed to post earnings of -$0.01 per share for Q3 2026.

The consensus revenue estimate for MariMed is $41.20 million for Q3 2026.

MariMed Earnings Headlines

MariMed Announces Third Quarter 2026 Earnings Date
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384240/0/en/marimed-announces-third-quarter-2026-earnings-date.html
MariMed’s Betty’s Eddies Spreads Importance of Cancer Screening Education and Awareness this October through Partnership with Keep A Breast Foundation
September 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/marimed-s-betty-s-eddies-spreads-importance-of-cancer-screening-education-and-awareness-this-october-through-partnership-with-keep-a-breast-foundation-1036570562
$29.97 or $0 today
The 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.tc pixel
 |  Profits Run (Ad)
MariMed's Betty's Eddies Spreads Importance of Cancer Screening Education and Awareness this October through Partnership with Keep A Breast Foundation
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368176/0/en/marimed-s-betty-s-eddies-spreads-importance-of-cancer-screening-education-and-awareness-this-october-through-partnership-with-keep-a-breast-foundation.html
MariMed cerca l’approvazione degli azionisti per un raggruppamento azionario inverso
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/company-news/marimed-cerca-lapprovazione-degli-azionisti-per-un-raggruppamento-azionario-inverso-93CH-3559259
MariMed Files Definitive Proxy Statement for Special Meeting of Stockholders to Approve Proposed Reverse Stock Split
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367326/0/en/marimed-files-definitive-proxy-statement-for-special-meeting-of-stockholders-to-approve-proposed-reverse-stock-split.html
See More MariMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MariMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MariMed and other key companies, straight to your email.

About MariMed

MariMed (OTCMKTS:MRMD), Inc. is a U.S.-based cannabis company that develops, operates, and manages state-licensed cannabis businesses. Its activities include cannabis cultivation, product manufacturing, wholesale distribution, and retail dispensary operations.

The company offers cannabis products such as flower, pre-rolls, concentrates, edibles, tinctures, and topical products. Its portfolio has included brands such as Betty’s Eddies, Nature’s Heritage, InHouse, and Kalm Fusion, which are distributed through MariMed-operated dispensaries and other licensed retail channels.

MariMed serves regulated cannabis markets in multiple states, including Massachusetts, Maryland, Delaware, and Ohio. The company was established in 2012 and has expanded through the development and acquisition of operating businesses in these markets. MariMed is led by Jon Levine, who serves as chief executive officer.

View MariMed Profile
Earnings Tools